← SynDRA
ALMOTRIPTAN
SynDRA canonical compound SYN0008311 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | HTR1D |
|---|
| Mechanism of action | Serotonin receptor agonist |
|---|
| Indication | migraine headache |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
Mechanisms of action (all sources)
- Serotonin receptor agonist
- HTR1F AGONIST
- Serotonin 1f (5-HT1f) receptor agonist
- HTR1B AGONIST
- Serotonin 1b (5-HT1b) receptor agonist
- HTR1D AGONIST
- Serotonin 1d (5-HT1d) receptor agonist
Drug classes
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Receptor Agonists
- Serotonin 1b Receptor Agonists
- Serotonin 1d Receptor Agonists
- Serotonin-1b and Serotonin-1d Receptor Agonist
ATC classes
- N02C · ANTIMIGRAINE PREPARATIONS
Cross-references
Synonyms
- almotriptan malate
- almogran
- axert
- LAS-31416
- LAS31416
- NSC-760092
- Almogran
- Axert
- Almotriptan (USAN)
- Axert (TN)
- PNU-180638
- Almotriptan [USAN:INN:BAN]
- N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
- N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine
- 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
- 1O4XL5SN61
- LAS 31416
- NSC 760092
- DTXCID3024289
- CHEBI:520985
- almotriptanum
- RefChem:57720
- N02CC05
- MFCD00927104
- NCGC00095135-01
- ALMOTRIPTAN [USAN]
- UNII-1O4XL5SN61
- CAS-154323-57-6
- SR-05000001986
- PNU 180638
- Spectrum_001884
- ALMOTRIPTAN [MI]
- Spectrum2_000498
- Spectrum3_001006
- Spectrum4_001134
- Spectrum5_001554
- ALMOTRIPTAN [INN]
- ALMOTRIPTAN [VANDF]
Reported adverse events
- Asthenia
- Chest pain
- Dizziness
- Dyspepsia
- Fatigue
- Myalgia
- Nausea
- Tachycardia
- Vomiting
- Abdominal discomfort
- Abdominal pain
- Abdominal pain upper
Look up ALMOTRIPTAN in the interactive SynDRA portal →